All In Biotech

Drug Trial Radar · NCT07369076

A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.

A Phase 1b/2 Study to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Mar 4, 2026

Primary completion

Apr 2027

Study completion Feb 2028

Sponsor

Lead sponsor
Nura BioIndustry
Sponsor type
Industry
First posted
Jan 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to learn about the effects of NB-4746 compared with placebo in people with amyotrophic lateral sclerosis. The questions this trial aims to answer in comparing NB-4746 to placebo are: * What adverse events associated with taking NB-4746 are reported during this trial? (An adverse event is any sign or symptom that participants have during a trial. Adverse events may or may not be caused by treatments in the trial.) * How does NB-4746 move into, through, and out of the body of the participants? * What is the change in the level of neurofilament light (NfL) in the participants' blood? (NfL is a marker used to measure the extent of damage to the nerve cells.) This trial has 2 parts. The trial doctors will start Part A before starting Part B of the trial. Participants have an option to enter the open label extension after completing Part A or Part B. Part A: Participants will be randomly placed into 1 of the 3 groups. There are equal chances to be assigned to either group. Group 1: Participants will receive NB-4746 capsules at a low dose to take by mouth twice daily for 1 month. Group 2: Participants will receive NB-4746 capsules at a high dose to take by mouth twice daily for 1 month. Group 3: Participants will receive placebo capsules to take twice daily for approximately 1 month. Part B: Participants will be randomly placed into 1 of the 2 groups. There are equal chances to be assigned to either group. Group 1: Participants will receive NB-4746 capsules at a dose determined by Part A to take by mouth twice daily for 12 weeks. Group 2: Participants will receive placebo capsules to take twice daily for approximately 12 weeks. None of the participants, trial doctors, or trial staff will know which treatment the participants will receive during Part A or B. Some trials are done this way because knowing what treatment the participants receive can affect the results of the trial. Doing a trial this way helps to make sure that the results are looked at with fairness across all treatments. Open-Label Extension: Upon the completion of Part A or Part B, the doctor will verify the participant's willingness to continue receiving study treatment. This open label extension continues until each participant completes up to 1 year of treatment. The trial doctors will check participants' ALS and general health throughout the trial.

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

  • NB-4746 High doseDrug

    NB-4746 will be administered twice daily in 2 capsules (high dose)

  • NB-4746 Low doseDrug

    NB-4746 will be administered twice daily in 2 capsules (low dose)

  • PlaceboDrug

    Two capsules of placebo will be administered twice daily.

  • NB-4746 (Dose TBD)Drug

    Two capsules of NB-4746 will be administered twice daily (dose will be defined after Ph 1b data is reviewed).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ph 1b - Number of TEAEs and SAEsTime frame: From enrollment to 28 days
  2. Evaluate safety and tolerability of NB-4746 in adult participants with ALS.Time frame: From enrollment to Week 12

Locations

12 sites in 4 countries. Site status is shown where the registry gives one.

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia · Recruiting

  • Neuroscience Research Australia

    Randwick, New South Wales, Australia · Recruiting

  • Royal Brisbane and Women's Hospital

    Brisbane, Queensland, Australia · Recruiting

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia · Recruiting

  • Calvery Health care Bethlehem

    Caulfield South, Victoria, Australia · Recruiting

  • Perron Institute

    Nedlands, Western Australia, Australia · Recruiting

  • Stan Cassidy Center for Rehabilitation

    Fredericton, New Brunswick, Canada · Recruiting

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada · Recruiting

  • Genge Partners

    Montreal, Quebec, Canada · Recruiting

  • UMC Utrect

    Utrecht, CX, Netherlands · Recruiting

  • Linden Sp. z o.o. sp.k.

    Krakow, Poland · Recruiting

  • CityClinic Research Sp. z o.o.

    Warsaw, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.